Research On The Risk Factors And Mechanism Of The New-onset Diabetes After Acute Pancreatitis

The new-onset diabetes is usual after the patients are recovery from acute pancreatitis for a long time.Our previous research showed the insulin resistance was the independent risk factor,the combined persistant organ failure and pancreatic necrosis increased the risk of the new-onset diabetes after AP.Chemerin was associated with the disease severity of AP and pancreatic necrosis.But whether the chemerin play a role in the regulation with the insulin resistance in patients with the new-onset diabetes after AP is still unclear and the scientific suggestion about prevention and medication for this kind of diabetes could not been provided.The research was studied by four aspects through both the clinical and animal trial.(1)Clinical research I:To dentify the morbidity and independent risk factor of the new-onset diabetes after AP by the follow-up study.(2)Clinical research II:To observe the difference of the chemerin between the new-onset diabetes and non-diabetes after AP,between the patients with insulin resistance(IR)and without IR after AP and between the patients with the new-onset diabetes after AP and the patients with T2D.(3)Animal trial I:To observe the dynamic change of the FBG,PBG,HOMA-IR,the plasma level of the chemerin,IL-1 and TNF-a and the expression of GLUT2 and PDX-1 in pancreatic tissue in T3cD model mice.(4)Animal trial Ⅱ:To illustrate the effect of the chemerin-9,the agonist of the chemerin receptor CMKLR1 on the insulin resistance and glucose metabolism of the T3cD model mice and the expression of the GLUT2 and PDX-1 in pancreatic tissues.The study clarified the morbidity,independent risk factors and insulin resistance of the new-onset diabetes after AP.And also illustrated chemerin played an important role in the regulation to the insulin resistance after AP.Chemerin may regulate the insulin resistance through the expression of GLUT2 and PDX-1 to increase the insulin secretion after the glucose stimulation by the chemerin-9,the agonist of the chemerin receptor CMKLR1.